A potential drug treatment for Parkinson’s dementia called ENT-01 improved cognitive function in some trial participants. During the 10-week treatment period these participants had better mental abilities such as remembering and problem-solving, and these continued to improve during the six weeks following treatment. The charity Parkinson’s UK has invested £2 million in phase 2 of the clinical trial, led by US biotech company Enterin. “While Parkinson’s is more commonly associated with motor symptoms like tremor, our community has asked us to make new and better treatments for Parkinson’s dementia a priority,” said Parkinson’s UK director of research Arthur Roach. “We are encouraged by the clinical results that Enterin’s work has produced to date and look forward to the upcoming clinical trial which will have sites in the UK as well as in America.”
